Evaluating Precision of Therapy - Milrinone

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

August 31, 2020

Study Completion Date

August 31, 2020

Conditions
Congenital Heart Disease
Interventions
DRUG

Milrinone

Milrinone is a potent selective phosphodiesterase (PDE) type III inhibitor which stimulates myocardial function (inotropy), causes peripheral vasodilatation (afterload reduction) and improves myocardial relaxation (lusitropy).

Trial Locations (2)

M5G 1X8

Hospital for Sick Children, Toronto

The Hospital for Sick Children, Toronto

All Listed Sponsors
lead

The Hospital for Sick Children

OTHER

NCT01841177 - Evaluating Precision of Therapy - Milrinone | Biotech Hunter | Biotech Hunter